Cargando…
Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study
BACKGROUND: The primary objective of this study was to determine the prevalence of neurocognitive impairment among HIV-positive individuals in Botswana, using the International HIV Dementia Scale (IHDS). We also compared performance on the IHDS with performance on tests of verbal learning/memory and...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876070/ https://www.ncbi.nlm.nih.gov/pubmed/20406460 http://dx.doi.org/10.1186/1758-2652-13-15 |
_version_ | 1782181655612489728 |
---|---|
author | Lawler, Kathy Mosepele, Mosepele Ratcliffe, Sarah Seloilwe, Esther Steele, Katherine Nthobatsang, Rudo Steenhoff, Andrew |
author_facet | Lawler, Kathy Mosepele, Mosepele Ratcliffe, Sarah Seloilwe, Esther Steele, Katherine Nthobatsang, Rudo Steenhoff, Andrew |
author_sort | Lawler, Kathy |
collection | PubMed |
description | BACKGROUND: The primary objective of this study was to determine the prevalence of neurocognitive impairment among HIV-positive individuals in Botswana, using the International HIV Dementia Scale (IHDS). We also compared performance on the IHDS with performance on tests of verbal learning/memory and processing speed, and investigated the association between performance on the IHDS and such variables as depression, age, level of education and CD4 count. METHODS: We conducted a cross-sectional study of 120 HIV-positive individuals randomly selected from an outpatient HIV clinic in Gaborone, Botswana. Patients provided a detailed clinical history and underwent neuropsychological testing; measures of depression, daily activities and subjective cognitive complaints were recorded. RESULTS: Despite the fact that 97.5% of subjects were receiving highly active antiretroviral therapy (HAART), 38% met criteria for dementia on the IHDS, and 24% were diagnosed with major depressive disorder. There was a significant association between neurocognitive impairment as measured by the IHDS and performance on the other two cognitive measures of verbal learning/memory and processing speed. Level of education significantly affected performance on all three cognitive measures, and age affected processing speed and performance on the IHDS. Depression and current CD4 count did not affect performance on any of the cognitive measures. CONCLUSIONS: The prevalence of neurocognitive impairment in HIV-positive individuals in Botswana is higher than expected, especially since almost all of the subjects in this study were prescribed HAART. This suggests the need to reconsider the timing of introduction of antiretroviral therapy in developing countries where HAART is generally not administered until the CD4 cell count has dropped to 200/mm(3 )or below. The contribution of other factors should also be considered, such as poor central nervous system penetration of some antiretrovirals, drug resistance, potential neurotoxicity, and co-morbidities. Memory impairment and poor judgment may be underlying causes for behaviours that contribute to the spread of HIV and to poor adherence. It is important to identify these neurobehavioural complications of HIV so that effective treatments can be developed. |
format | Text |
id | pubmed-2876070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-28760702010-05-26 Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study Lawler, Kathy Mosepele, Mosepele Ratcliffe, Sarah Seloilwe, Esther Steele, Katherine Nthobatsang, Rudo Steenhoff, Andrew J Int AIDS Soc Research BACKGROUND: The primary objective of this study was to determine the prevalence of neurocognitive impairment among HIV-positive individuals in Botswana, using the International HIV Dementia Scale (IHDS). We also compared performance on the IHDS with performance on tests of verbal learning/memory and processing speed, and investigated the association between performance on the IHDS and such variables as depression, age, level of education and CD4 count. METHODS: We conducted a cross-sectional study of 120 HIV-positive individuals randomly selected from an outpatient HIV clinic in Gaborone, Botswana. Patients provided a detailed clinical history and underwent neuropsychological testing; measures of depression, daily activities and subjective cognitive complaints were recorded. RESULTS: Despite the fact that 97.5% of subjects were receiving highly active antiretroviral therapy (HAART), 38% met criteria for dementia on the IHDS, and 24% were diagnosed with major depressive disorder. There was a significant association between neurocognitive impairment as measured by the IHDS and performance on the other two cognitive measures of verbal learning/memory and processing speed. Level of education significantly affected performance on all three cognitive measures, and age affected processing speed and performance on the IHDS. Depression and current CD4 count did not affect performance on any of the cognitive measures. CONCLUSIONS: The prevalence of neurocognitive impairment in HIV-positive individuals in Botswana is higher than expected, especially since almost all of the subjects in this study were prescribed HAART. This suggests the need to reconsider the timing of introduction of antiretroviral therapy in developing countries where HAART is generally not administered until the CD4 cell count has dropped to 200/mm(3 )or below. The contribution of other factors should also be considered, such as poor central nervous system penetration of some antiretrovirals, drug resistance, potential neurotoxicity, and co-morbidities. Memory impairment and poor judgment may be underlying causes for behaviours that contribute to the spread of HIV and to poor adherence. It is important to identify these neurobehavioural complications of HIV so that effective treatments can be developed. The International AIDS Society 2010-04-20 /pmc/articles/PMC2876070/ /pubmed/20406460 http://dx.doi.org/10.1186/1758-2652-13-15 Text en Copyright ©2010 Lawler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Lawler, Kathy Mosepele, Mosepele Ratcliffe, Sarah Seloilwe, Esther Steele, Katherine Nthobatsang, Rudo Steenhoff, Andrew Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title | Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title_full | Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title_fullStr | Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title_full_unstemmed | Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title_short | Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study |
title_sort | neurocognitive impairment among hiv-positive individuals in botswana: a pilot study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876070/ https://www.ncbi.nlm.nih.gov/pubmed/20406460 http://dx.doi.org/10.1186/1758-2652-13-15 |
work_keys_str_mv | AT lawlerkathy neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT mosepelemosepele neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT ratcliffesarah neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT seloilweesther neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT steelekatherine neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT nthobatsangrudo neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy AT steenhoffandrew neurocognitiveimpairmentamonghivpositiveindividualsinbotswanaapilotstudy |